Coronavirus.

Status
Not open for further replies.

Blue_boost

Kennel Enthusiast
Joined
May 19, 2014
Messages
4,012
Reaction score
2,210
Who wants to trial for thekennel gridiron team?

We assemble one morning at Coles to hold out the crowd trying to stampede and then I'll go in and buy a pallet of toilet paper ..

The team keeps the mob off, to let me drive away and then I'll distribute to the team thereafter?

Who's in? Need big units who fight dirty if need be.
 

south of heaven

Kennel Immortal
Premium Member
Joined
Mar 6, 2014
Messages
29,247
Reaction score
25,695
Glad I picked Perth over Sydney must be be crazy there now.
13-year-old girl has been left injured and crying on the ground after panic buyers stormed a Coles to buy toilet paper.

The girl's mother, who is currently wheelchair-bound due to a recent operation, said she went to the Coles in Baldivis, Perth, today to buy toilet paper and snacks with her daughter and nine-year-old
 

Alan79

Kennel Legend
Joined
Mar 10, 2007
Messages
13,221
Reaction score
19,003
This bloke did an Izzy...

When did Izzy cop an unexpected Nob up his poop chute?

That is some 007 level investigation done right there! If this virus was created by a man it would develop a protein deficiency in woman that can only be alleviated by ingesting spermatozoa orally. The incubation period would be 10-15 years and laws would be enacted where men would be forced to allow any woman to give them a blowjob at any time anywhere. It would against the law for your partner to object to a woman wanting to suck your balls dry to alleviate the virus symptoms and there would no synthetic substitute.
Many might think that's a great proposition, but remember that there are ladies like Raylene Castle, Rebecca 'man head' Wilson, Susan Boyle etc doing the rounds. And just imagine if you went to visit your grandma who started coughing and you were the only fellow around. Theoretically a good thing, but in practice it might give men nightmares.

Oh it's coming - did you see the news story about Los Angelenos lining up at gun stores?
What a novel idea - shoot the virus. And if not the virus, each other.
I say leave it to Walker Texas Ranger - he'll karate the shit out of anything.
I felt like a bank robber earlier. I was at Cole's and conscious of not touching my face with an itching nose. I eventually had to sneeze. People almost dived for cover.

Jesus. 'Alexa, release mustard gas on home owner'.
If you've ever heard Alexa doing the evil laugh early in the morning, you'd think twice about giving her access to the guns.
 

Lov_Dog

Kennel Enthusiast
Joined
Apr 8, 2008
Messages
2,994
Reaction score
1,697
@Hacky McAxe ... in your broad exposure to corona-related content, any research involving recovered case harvesting of antibodies for immunization purposes?
Rather than an attenuated vaccine approach, is there possibility of an antibody transplant?
 

Hacky McAxe

Super Moderator
Staff member
Moderator
Gilded
Joined
May 7, 2011
Messages
37,040
Reaction score
29,418
New data released by NSW Health when the number of cases in the state was at 210 shows that the majority of cases in the state are from women aged 30 to 39.
Joseph fritzel was right women need to kept in a cellar
If you read the research coming out of China it shows that men are more likely to die from Coronavirus. So it's probably a feminist virus.
 

Mr 95%

Kennel Immortal
Gilded
Joined
Apr 13, 2013
Messages
22,205
Reaction score
22,904
The race to find a coronavirus treatment: One strategy might be just weeks away, scientists say


MARK JOHNSON | MILWAUKEE JOURNAL SENTINEL

12:26 pm EDT Mar. 15, 2020

MILWAUKEE, Wis. – In a week when the coronavirus closures and quarantines hit like falling dominoes – the lockdown in Italy, the empty workplaces and college campuses in the U.S., suspended sports seasons, canceled festivals – far less attention fell on the global scientific community's drive to find treatments for the new virus.

But researchers are already suggesting strategies to help patients suffering from the virus, which is marked by fever, coughing and difficulty breathing. One treatment could be just weeks away.

With no vaccine expected anytime soon, treatments are crucial to saving the lives of thousands of the infected, especially high-risk patients – the elderly, those with compromised immune systems and those with chronic illnesses, such as diabetes, heart disease and lung disease.

"I'm very hopeful and very positive. We'll get through this," said Robert Kruse, a doctor in the Department of Pathology at Johns Hopkins Hospital in Baltimore. "I've been shocked this week at the measures that have been taken (to alter daily life). They were probably the correct ones, given that they have worked in other countries."

'Time is of the essence'

Kruse has been pursuing two different treatment strategies, one of which has a long history and could be available within weeks rather than months. The quickest option is likely to be the use of antibodies from recovered COVID-19 patients. As of Saturday, there were almost 72,000 such patients worldwide. The virus has infected about 150,000, killing more than 5,500.

The use of survivor antibodies, serum therapy, dates back to 1891 when it was used successfully to treat a child with diphtheria. Since then, serum from recovered patients has been used "to stem outbreaks of viral diseases such as poliomyelitis, measles, mumps and influenza," according to a paper Friday in The Journal of Clinical Investigation.

"As we are in the midst of a worldwide pandemic, we recommend that institutions consider the emergency use (of serum from recovered patients) and begin preparations as soon as possible. Time is of the essence," wrote the paper's two authors, Arturo Casadevall of Johns Hopkins School of Public Health, and Liise-anne Pirofski of the Albert Einstein College of Medicine in New York.

All of the strategies, including the use of serum from recovered patients, have drawbacks. Transfusion of serum carries potential side effects, including fever, allergic reactions, and a very small risk of infectious disease transmission.

Collecting large amounts of serum from recovered patients could be a sizable task. It could turn out that serum from one recovered patient is only enough to save a single sick one, explained Kruse at Johns Hopkins. "It's a logistical challenge to put it together, but at the very least there are no hurdles (from the U.S. Food and Drug Administration) to producing the therapy."

Kruse advanced another technique in a paper published in late January in the journal F1000 Research.

His method seeks to take advantage of the new coronavirus' ability to latch onto and enter cells.

Scientists often talk about "cell receptors," which are essentially doors that allow a virus to enter the cell.

The "door" the new coronavirus is entering through is known as the ACE-2 protein. Kruse's technique involves detaching the external portion of ACE-2, which would act as a decoy for the virus. The virus would bind to the decoy, leaving it unable to reach the actual door into the cell, and thus, unable to cause infection.

"It won't realize, 'Oh gosh, this isn't a cell,'" Kruse explained in an interview. "The virus can't mutate away from this."

Kruse's decoy therapy would not be available until fall at the earliest. However, a similar version of the strategy is currently being tested in trials in China.

Using a drug for a new purpose

A faster option involves what's called "repurposing" a drug.

This is when a drug that has already been found safe and approved for treatment of one disease also is found useful in treating another. One example is the drug Sildenafil, which is sold as Viagra and used to treat both erectile dysfunction and pulmonary hypertension.

There are three ways in which scientists try to find an existing drug that can treat a new condition.

The rational method involves using drugs that have characteristics and targets that suggest they might be used to treat the new condition.

The computational method involves examining protein structures and using them to predict an existing drug that might work.

The final method takes advantage of the vast drug libraries possessed by companies and academic institutions. High-speed technology allows researchers to screen thousands of drugs very quickly to determine whether they will act against a specific target.

Considerable hope, interest and money have been invested in one drug not previously approved, remdesivir. The drug was previously tested against Ebola, but failed in trials.

Gilead Sciences, a Foster City, California-based biopharmaceutical company, announced that two clinical studies of the drug are beginning this month. Two more clinical trials of the drug are already underway in China.

In the U.S., the clinical trials process is slow and painstaking, taking several years and sometimes much longer.

'The idea is right'

Another approach to the new virus championed by numerous researchers is the use of lab-made proteins called monoclonal antibodies.

These confer what's called "passive immunity" and have been used previously to treat cancer, multiple sclerosis, cardiovascular disease and many other conditions.

"The use of monoclonal antibodies is a new era in infectious disease prevention which overcomes many drawbacks associated with serum therapy ... in terms of specificity, purity, low risk of blood-borne pathogen contamination and safety," wrote the authors of a recent paper in the Asian Pacific Journal of Allergy and Immunology.

The biotechnology company Regeneron, based in Tarrytown, New York, started work searching for a monoclonal antibody "for this particular virus in early/mid-January," said Christos Kyratsous, the company's vice president for infectious diseases and viral vector technologies. "But really we started working on it decades ago when we began building our unique end-to-end drug discovery and development technologies."

Gregory Poland, director of Mayo Clinic's Vaccine Research Group, said the use of monoclonal antibodies "needs to be designed and tested in this specific disease, but I wouldn't see any reason it wouldn't work. The idea is right."

Like other scientists, Poland was less hopeful that a vaccine would be developed anytime soon.

"We won't have a vaccine for this outbreak," he said. "It will be before the next (outbreak)."

Monoclonal antibodies do have pitfalls. They require extensive testing. Also, viruses can mutate and escape from the antibodies. Companies sometimes target two different parts of the virus to make it harder for the virus to mutate and elude the antibodies.

Ajay K. Sethi, associate professor of population health sciences at the University of Wisconsin-Madison, expressed support for the development of monoclonal antibodies.

"In my opinion, trying a strategy like monoclonal antibodies to provide passive immunity is a good idea," Sethi said. He added that given the technique's past successes, "it is hopeful, but not surprising."

Strategies for combating the new coronavirus will likely require reaching patients early before they get too sick. Toward that end, Kruse said he believes the U.S. should pursue the much broader coronavirus testing policy that South Korea adopted.

"Maybe in the next few weeks we will get to the point where we are testing everyone," he said.

12:26 pm EDT Mar. 15, 2020

What do you think @Hacky McAxe and @Lov_Dog and any other Science minded people on the Kennel?
@Lov_Dog remember this..as it’s the way I live my life in my personal prison..my body.. So that’s the way I look at this.

24476DE1-1564-458A-A52A-A2E0ECAC9BAD.jpeg
 

KambahOne

Kennel Enthusiast
Joined
Jul 3, 2019
Messages
3,659
Reaction score
4,735
Many might think that's a great proposition, but remember that there are ladies like Raylene Castle, Rebecca 'man head' Wilson, Susan Boyle etc doing the rounds. And just imagine if you went to visit your grandma who started coughing and you were the only fellow around. Theoretically a good thing, but in practice it might give men nightmares.
You just gave me some. :sob:
 

Hacky McAxe

Super Moderator
Staff member
Moderator
Gilded
Joined
May 7, 2011
Messages
37,040
Reaction score
29,418
If Italy has over 2500 dead I wonder what the true Chinese and Iranian count would be
China "reported" numbers are 3,237 and Iran "reported" numbers are 988, so multiply those by 10 and you're probably close.
 

Hacky McAxe

Super Moderator
Staff member
Moderator
Gilded
Joined
May 7, 2011
Messages
37,040
Reaction score
29,418
13-year-old girl has been left injured and crying on the ground after panic buyers stormed a Coles to buy toilet paper.

The girl's mother, who is currently wheelchair-bound due to a recent operation, said she went to the Coles in Baldivis, Perth, today to buy toilet paper and snacks with her daughter and nine-year-old
And that was a few months ago...
 

The DoggFather

OG DF
Premium Member
Gilded
Site's Top Poster
Joined
Sep 2, 2012
Messages
106,433
Reaction score
117,590
Who wants to trial for thekennel gridiron team?

We assemble one morning at Coles to hold out the crowd trying to stampede and then I'll go in and buy a pallet of toilet paper ..

The team keeps the mob off, to let me drive away and then I'll distribute to the team thereafter?

Who's in? Need big units who fight dirty if need be.
Sounds like fun. I'm in lol
 

Lov_Dog

Kennel Enthusiast
Joined
Apr 8, 2008
Messages
2,994
Reaction score
1,697
@Lov_Dog remember this..as it’s the way I live my life in my personal prison..my body.. So that’s the way I look at this.

View attachment 13777

@Mr 95%, I copy/pasted the title in google to find original article .. and couldn't read due to my ad blocker ...
It describes exactly what I was thinking.
Regeneron are massive and their stock is headed top right.

Chin up my friend!
 

Hacky McAxe

Super Moderator
Staff member
Moderator
Gilded
Joined
May 7, 2011
Messages
37,040
Reaction score
29,418
@Hacky McAxe ... in your broad exposure to corona-related content, any research involving recovered case harvesting of antibodies for immunization purposes?
Rather than an attenuated vaccine approach, is there possibility of an antibody transplant?
I haven't seen research on it yet but I know there are a few pharmaceutical companies working on it. Most are trying to gather antibodies of recovered patients. Regeneron are using genetically altered mice with human like immune systems and injecting them with the virus to develop antibodies. They did this when treating an outbreak of Ebola and it was successful then.

Obviously their way has the downside that it'll take a lot of time, but the other companies are having trouble getting blood samples to develop test an antibody transfer.

Regeneron are planning to start trials in about 3-6 months.
 

Mr 95%

Kennel Immortal
Gilded
Joined
Apr 13, 2013
Messages
22,205
Reaction score
22,904
@Mr 95%, I copy/pasted the title in google to find original article .. and couldn't read due to my ad blocker ...
It describes exactly what I was thinking.
Regeneron are massive and their stock is headed top right.

Chin up my friend!
Excellent...My chin is up it’s part of my neck brace..



Bahahaha bahahaha..it’s not!!


Ps..sick wheelchair humour is my ally..:tearsofjoy::tearsofjoy::tearsofjoy::tearsofjoy::tearsofjoy:
 
Status
Not open for further replies.
Top